Abstract 4486: Characterization of a novel mutant selective, EGFR sparing, ErbB2 inhibitor with activity across activating mutations in systemic and CNS tumors

Abstract

Abstract Alterations in ErbB2, including amplification, overexpression, insertions, and point mutations, are established oncogenic drivers in many solid tumors. These mutations are found in approximately 3-4% of breast cancers and 3% of advanced lung cancers and have emerged as mechanisms of acquired resistance to targeted therapies. ErbB2 alterations are also found in metastatic breast and lung cancers that have advanced to the brain and remain a major clinical challenge with limited therapeutic options. Currently approved ErbB2 tyrosine kinase inhibitors have inferior potency against these mutations and lack sufficient brain penetration to be an impactful treatment option for patients. Herein, we describe advanced preclinical profiling of our candidate series of brain-penetrant EGFR-sparing ErbB2 inhibitors with activity against prevalent point mutations and exon 20 YVMA insertions. Citation Format: Jennifer Fulton, Tanna Bettendorf, Abiezer Blandon, Karyn Bouhana, Richard K. Brizendine, LouAnn Cable, Mark J. Chicarelli, Michelle Crow, Brad Fell, John Fischer, Anna Guarnieri, Madison Hillman, Ravi Jalluri, Vijay Kumar, Cori A. Malinky, Rob Rieger, John Robinson, Lee Stunkard, Francis Sullivan, John I. Trujillo, Shannon Winski, Yeyun Zhou. Characterization of a novel mutant selective, EGFR sparing, ErbB2 inhibitor with activity across activating mutations in systemic and CNS tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4486.